OncoMatch/Clinical Trials/NCT06144606

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Is NCT06144606 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tecartus for b-cell lymphoblastic leukemia.

Phase 2RecruitingH. Lee Moffitt Cancer Center and Research InstituteNCT06144606Data as of May 2026

Treatment: Tecartus — This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Lymphoblastic Leukemia

Biomarker criteria

Required: CD19 positive

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: induction chemotherapy — induction

Treatment and full recovery from induction chemotherapy, with following exceptions: Vincristine associated grade 1 peripheral neuropathy; Steroid/asparaginase associated diabetes and/or hypertension; Inotuzumab/chemotherapy associated cytopenias

Lab requirements

Blood counts

adequate hematopoietic reserve

Kidney function

adequate renal function

Liver function

adequate hepatic function

Cardiac function

adequate cardiac function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Moffitt Cancer Center · Tampa, Florida

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify